| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | Sidewinder pockets $137m in Series B to take bispecific ADCs to clinic | ||
| Mi | RoosterBio and MineBio team up to expand MSC solutions access in China | ||
| Mi | Pharma industry laments Trump's tariff on branded drugs | ||
| Mi | Halozyme and Vertex sign deal for Hypercon technology | ||
| Di | Gilead outlays $5bn to acquire ADC specialist Tubulis | ||
| Di | Apnimed obtains up to $150m in funds for commercial launch of AD109 | ||
| Di | Neurocrine to acquire Soleno in $2.9bn transaction | ||
| Mo | Aspect Biosystems receives funding for cellular medicine project | ||
| Mo | MSD secures EC clearance for Keytruda combination therapy for ovarian cancer | ||
| 02.04. | Eli Lilly wins FDA approval for weight loss pill, tees up Novo rivalry | ||
| 02.04. | Merck KGaA acquires JSR chromatography business | ||
| 02.04. | Biocytogen and Sihuan partner to advance new therapeutics for weight loss | ||
| 01.04. | Eli Lilly outlays $7.8bn to acquire sleep drug biotech Centessa | ||
| 01.04. | Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout | ||
| 01.04. | Eli Lilly outlays $7.3bn to acquire sleep drug biotech Centessa | ||
| 01.04. | Telomir seeks FDA approval for Telomir-1 to treat breast cancer | ||
| 01.04. | Symeres and Ambagon collaborate for colorectal cancer molecules | ||
| 31.03. | Teva receives FDA approval for Prolia biosimilar | ||
| 31.03. | Blackstone closes largest ever private funding investment round at $6.3bn | ||
| 31.03. | uBriGene and Cellinfinity BIO collaborate to accelerate in vivo CAR-T therapies | ||
| 30.03. | Otsuka agrees to acquire Transcend Therapeutics for $1.22bn | ||
| 30.03. | Eli Lilly and Insilico Medicine forge $2.75bn AI-driven R&D pact | ||
| 30.03. | Novo Nordisk secures FDA approval for basal insulin Awiqli | ||
| 27.03. | Recordati sizes up €10.9bn CVC Capital acquisition offer | ||
| 27.03. | J&J's Darzalex nets first self-administered cancer injectable approval |